Braun Stacey Associates Inc Neurocrine Biosciences Inc Transaction History

Braun Stacey Associates Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 31, 2019	SELL	$83.82 - $101.5 $199,407 - $241,468	-2,379 Closed	0 $0
Q2 2019 Jul 25, 2019	SELL	$72.24 - $91.27 $5.36 Million - $6.77 Million	-74,148 Reduced 96.89%	2,379 $201,000
Q1 2019 Apr 25, 2019	SELL	$69.31 - $91.53 $2.11 Million - $2.78 Million	-30,410 Reduced 28.44%	76,527 $6.74 Million
Q4 2018 Jan 28, 2019	SELL	$68.32 - $124.36 $3.12 Million - $5.68 Million	-45,637 Reduced 29.91%	106,937 $7.64 Million
Q3 2018 Oct 29, 2018	BUY	$98.88 - $125.85 $660,518 - $840,678	6,680 Added 4.58%	152,574 $18.8 Million
Q2 2018 Aug 01, 2018	BUY	$75.3 - $105.99 $11 Million - $15.5 Million	145,894 New	145,894 $14.3 Million

641

95.2M

661K

227K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Braun Stacey Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Braun Stacey Associates Inc with notifications on news.